Efficacy of 0.2% brimonidine in combination therapy for patients with primary open-angle glaucoma and axial myopia
https://doi.org/10.25700/NJG.2019.03.04
Abstract
PURPOSE: To assess the possibility of glaucoma compensation and stabilization in patients with a combination of primary open-angle glaucoma (POAG) and axial myopia on 0.2% brimonidine as part of combination glaucoma therapy.
METHODS: We conducted a clinical results analysis of a 1-year treatment program of 30 patients with a combination of non-compensated POAG and axial myopia. All patients underwent an ophthalmologic examination that was sufficient to verify the diagnosis, as well as an analysis of the morphometric parameters of the retina and optic nerve using Cirrus HD OCT 4000. 0.2% brimonidine instillation was added to the treatment 2 times day as part of the hypotensive treatment.
RESULTS: Adding 0.2% brimonidine to the course of treatment in patients with POAG and axial myopia allowed achieving IOP compensation and reducing the initial IOP level by 25.3-29.9%. No statistically significant changes in visual acuity and perimetry data were registered during the year of observation. There were no changes in OCT parameters, which demonstrated a stable condition of the optic disc and retina during the treatment course.
CONCLUSION: The use of 0.2% brimonidine as part of combination glaucoma therapy in patients with POAG and axial myopia is expedient and effective.
About the Authors
E. N. Eskina
Ophthalmological clinic «Sphere»
Russian Federation
Russian Federation
M.D., Professor, Chief physician
10 st. Starokachalovskaya, Moscow, 117628
A. V. Belogurova
Ophthalmological clinic «Sphere»
Russian Federation
Russian Federation
Ph.D., ophthalmologist
10 st. Starokachalovskaya, Moscow, 117628
References
1. Glaucoma for medical practitioners: national guidance. 3rd ed. Ed. by E.A. Egorov, Yu.S. Astakhov, V.P. Erichev. Moscow: GEOTAR-Media Publ.; 2015. 456 p. (In Russ.).
2. Tham Y.C., Li X., Wong T.Y., Quigley H.A., Aung T., Cheng C.Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014; 121(11):2081–2090. doi:10.1016/j.ophtha.2014.05.013
3. Neroev V.V., Avdeev R.V., Kiseleva O.A., Bessmertnyi A.M. Some results of epidemiological studies of glaucoma in 2011. Oftal’mologicheskie vedomosti. 2014; 7(2):4-8. (In Russ.)
4. Glaucoma. National guidance. Ed. by E.A. Egorov. Moscow: GEOTARMedia Publ.; 2013. 824 p. (In Russ.).
5. Akopyan A.I., Erichev V.P., Iomdina E.N. The value of biomechanical parameters of the eye in the interpretation of the development of glaucoma, myopia and comorbidity. Glaucoma. 2008; 1(7):9-14. (In Russ.).
6. Xu S., Xu A., Tao A., Wang J. et al. Corneal biomechanical properties and intraocular pressure in high myopic anisometropia. Eye Contact Lens. 2010; 36(4):204-209. doi: 10.1097/ICL.0b013e3181e4a60a
7. Usui S., Ikuno Y., Miki A., Matsushita K. et al. Evaluation of the choroidal thickness using high-penetration optical coherence tomography with long wavelength in highly myopic normal-tension glaucoma. Am J Ophthalmol. 2012; 153(1):10-16. doi: 10.1016/j.ajo.2011.05.037
8. Liu Y., Wang Y., Lv H., Jiang X. et al. α-adrenergic agonist brimonidine control of experimentally induced myopia in guinea pigs: a pilot study. Mol Vis. 2017; 23:785-798.
9. Schmidl D., Schmetterer L., Gar er G., Popa-Cherecheanu A. Pharmacotherapy of Glaucoma. J Ocul Pharmacol Ther. 2015; 31(2):63-77. doi: 10.1089/jop.2014.0067
10. Toris C.B., Camras C.B., Yablonski M.E. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am J Ophthalmol. 1999; 128(1):8-14. doi: 10.1016/s00029394(99)00076-8
11. Dugina A.E. Selective of alfa2-adrenoceptor agonists in glaucoma treatment. Natsional’nyi zhurnal glaucoma. 2014; 3:95-100. (In Russ.).
12. Lebedev O.I., Chetvergova O.E., Surov A.V., Pechk T.A. et al. Pathogenetic mechanisms of the hypotensive action of ø2-adrenomimetics. Natsional’nyi zhurnal glaucoma. 2017; 16(2):19-26. (In Russ.).
13. Oganezova Zh.G., Egorov E.A. Features of therapy in patients with glaucoma and dry eye syndrome. Klinicheskaya oftal’mologiya. 2018, 1:1-4. (In Russ.).
14. Kim C.Y., Hong S., Song G.J. Brimonidine 0.2% versus brimonidine Purite 0.15% in Asian ocular hypertension. J Ocul Pharmacol Ther. 2007; 23:481-486. doi: 10.1089/jop.2007.0042
15. Hernаndez M., Urcola J.H., Vecino E. Retinal ganglion cell neuroprotection in a rat model of glaucoma following brimonidine, latanoprost or combined treatments. Exp Eye Res. 2008; 86:798-806. doi:10.1016/j.exer.2006.01.025
16. WoldeMussie E., Ruiz G., Wijono M., Wheeler L.A. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci. 2001; 42:2849-2855.
17. Lambert W.S., Ruiz L., Crish S.D., Wheeler L.A. et al. Brimonidine prevents axonal and somatic degeneration of retinal ganglion cell neurons. Mol Neurodegener. 2011; 6:4. doi: 10.1186/1750-1326-6-4
18. Lоpez-Herrera M.P.L., Mayor-Torroglosa S., de Imperial J.M., Villegasrez M.P. et al. Transient ischemia of the retina results in altered retrograde axoplasmic transport: neuroprotection with brimonidine. Exp Neurol. 2002; 178:243-258.
19. Lee D., Kim K., Noh Y.H., Chai S. et al. Brimonidine blocks glutamate excitotoxicity-induced oxidative stress and preserves mitochondrial transcription factor a in ischemic retinal injury. PLoS One. 2012; 7. doi: 10.1371/journal.pone.0047098
20. Dong C.J., Guo Y., Agey P., Wheeler L. et al. Alpha2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity. Invest Ophthalmol Vis Sci. 2008; 49:4515-4522. doi: 10.1167/iovs.08-2078
21. Fujita Y., Sato A., Yamashita T. Brimonidine promotes axon growth after optic nerve injury through Erk phosphorylation. Cell Death and Disease. 2013; 4:e763. doi:10.1038/cddis.2013.298
22. Erb C., Gast U., Schremmer D. German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye. Graefes Arch Clin Exp Ophthalmol. 2008; 246(11):1593–1601. doi: 10.1007/ s00417-008-0881-9
23. Erichev V.P., Ambartsumyan K.G. Preservatives and secondary syndrome of “dry eye” in long-term local drug therapy of primary open-angle glaucoma. Glaukoma. 2011; 2:59–66. (In Russ.).
24. Yegorova G.V., Averich V.V. the Reduction of the cytotoxic effect of the preservative in the composition of ophthalmic antihypertensive drugs with the help of tear therapy. Vestnik oftal’mologii. 2018; 134(3): 48–56. (In Russ.).
Review
For citations:
Eskina E.N., Belogurova A.V. Efficacy of 0.2% brimonidine in combination therapy for patients with primary open-angle glaucoma and axial myopia. National Journal glaucoma. 2019;18(3):35-42. (In Russ.) https://doi.org/10.25700/NJG.2019.03.04
Views:
669
Email this article 